made for GWAS and SV in 50,000 SCZ cases and 50,000 controls 140 ). Based on the recent ASD studies, sequencing directed at rare and de novo variation will have a role in a balanced portfolio of approaches. 83–85 Indeed, with improvements in accuracy, coverage, and pricing, it is possible that sequencing could evolve into the technology of choice for genotyping all major classes of genetic variation.
